- First-in-Class Analysis of an AI-Pushed Candidate: That is the primary de-novo drug designed with generative AI for a de-novo goal found utilizing AI and Ageing Analysis (AI getting older clocks, AI fashions and Hallmarks of Ageing Evaluation).
- First Common Consensus Throughout Six Independently-Developed Proteomic Ageing Clocks: Analyzing 12-week longitudinal Olink proteomic knowledge from 42 IPF sufferers, six getting older clock fashions (together with ProtAge, OrganAge, and PAC) independently developed by the main teams from Harvard, Oxford, PKU, and Insilico, unanimously indicated that rentosertib reversed predicted organic age.
- First Scalable Blueprint for Twin-Goal Medical Trials: The examine is the primary demonstration of a novel drug for a novel goal found utilizing getting older analysis purposed to the age-related illness with getting older biomarkers utilized in a context of a scientific examine. It establishes a standardized framework for embedding geroscience endpoints into normal illness trials, aligned with FDA Biomarker/BEST pointers for dual-purpose getting older and illness therapeutics.
CAMBRIDGE, Mass., Sept. 7, 2026 /PRNewswire/ — Insilico Drugs (“Insilico”), a clinical-stage firm centered on generative AI-driven drug discovery and improvement, in the present day introduced the publication of a brand new examine carried out in collaboration with a world crew of scientists from Harvard Medical College, Stanford College, The Broad Institute, RWTH Aachen College, Peking College and Westlake College.
Utilizing longitudinal Olink proteomic knowledge (CNCB OMIX accession: OMIX008341) collected throughout a Part IIa scientific trial of rentosertib, researchers evaluated organic age utilizing six internationally acknowledged, independently developed proteomic getting older clocks. All six fashions constantly indicated a discount in predicted organic age amongst sufferers handled with rentosertib. As well as, the Pressured Important Capability (FVC), the important measure of lung operate declining with age, confirmed promising dose-dependent reversal in comparison with placebo aligning with the proteomic getting older clock age reversal.
Not too long ago printed in Nature Biotechnology, the examine represents the primary scientific analysis of a probably first-in-class drug candidate that includes each an AI-discovered goal with relevance to getting older and illness biology and an AI-designed molecule, somewhat than a repurposed generic drug resembling rapamycin or metformin. The findings additionally present a proof-of-concept framework for integrating getting older biomarkers into normal scientific trials to speed up the invention of geroprotective medicine and longevity therapeutics.
The outcomes might be offered by first creator Alex Zhavoronkov, founder and CEO of Insilico Drugs, on the Nature convention: Redefining Healthcare within the Age of AI, to be held at Sorbonne College in Paris on September 8, 2026.
From getting older biology to a scientific drug
In contrast to conventional geroscience research that depend on repurposed medicine like rapamycin or metformin, Insilico pursued a distinct method by incorporating getting older biology into its drug discovery technique from the outset.
Utilizing its AI-powered goal discovery platform, Insilico recognized TNIK as a novel goal implicated in getting older and fibrosis and carried out hallmarks of aging evaluation the place TNIK scored extremely in 6 hallmarks. TNIK was subsequently prioritized as a dual-purpose goal related to each underlying aging biology and idiopathic pulmonary fibrosis (IPF). Insilico’s generative chemistry platform, Chemistry42, was then deployed to design the small-molecule candidate rentosertib concentrating on TNIK. This system progressed from goal identification to preclinical candidate nomination in roughly 18 months, with the preclinical findings printed in Nature Biotechnology in 2024.
In June 2025, Insilico reported the outcomes of a Part IIa trial of Rentosertib for IPF (NCT05938920) in Nature Medicine. The trial met its main security endpoint and demonstrated a promising dose-dependent development in efficacy. One of many widespread efficacy consequence measures is Pressured Important Capability (FVC), the important measure of lung operate. The everyday age of onset of IPF is round 65 years. Curiously, in wholesome people older than 65, FVC declines as properly usually on the price of 20-50 mL/12 months and might also function a possible physiological biomarker of getting older. Within the earlier publication, it was revealed that within the 60-mg once-daily group, sufferers skilled a imply enchancment in pressured very important capability (FVC) of +98.4 mL, in contrast with a imply decline of -20.3 mL within the placebo group (-62.3 excluding outlier).
Crucially, the trial protocol prospectively included longitudinal serum proteomic screening for exploratory biomarker analyses, which proved in step with the drug’s proposed anti-fibrotic and anti inflammatory exercise. All knowledge collected from the trial have been subsequently deposited with the China Nationwide Heart for Bioinformation (CNCB), enabling the present investigation of organic getting older biomarkers.
Six completely different clocks level to sturdy organic age reversal measured by proteomics
Within the present examine, researchers evaluated serum proteome profiles from 42 trial individuals throughout 2,841 proteins. The crew utilized six independently developed proteomic getting older clocks, together with ProtAge, OrganAge (chronological and mortality variants), PAC, ipfP3GPT, and PAOPAC. Regardless of counting on numerous methodologies and coaching standards, all six clocks constantly exhibited a development towards reversed organic age amongst rentosertib-treated sufferers in comparison with placebo. The height impact is noticed at Week 4 in individuals receiving 30 mg BID with roughly 3-4 years reversal in organic age and as much as 6 years in a sure getting older clock.
Past modifications in organic age scores, the examine confirmed that rentosertib’s anti-aging results function partially impartial of its respiratory advantages. Notably, the dose related to the best enchancment in lung operate differed from that producing the strongest age-reversal sign, suggesting that the drug’s geroprotective exercise was not merely a downstream consequence of illness enchancment.
This systemic influence was additional validated by way of comparisons with 55,319 UK Biobank profiles, which confirmed that rentosertib immediately reversed the everyday age-related protein-expression trajectories. Mechanistically, the drug acted as a senomorphic agent, suppressing key drivers of mobile senescence, together with EREG, ESM1, IGFBP4, ITGA2, MMP10, MMP13, and SPP1 whereas downregulating growth-factor signaling pathways related to accelerated getting older, together with RTK-PI3K and RAS-ERK, and modulating antioxidant and ldl cholesterol metabolisms.
A framework for the long run
To assist reproducibility and additional analysis, all analysis knowledge have been deposited at CNCB (accession OMIX008341), and the underlying pipeline code has been printed because the open-source Python library on GitHub.
Past these particular findings, the examine lays out a scalable blueprint for embedding geroscience endpoints into disease-focused drug improvement. The analysis proposes a stepwise framework: accumulating getting older and senescence biomarkers prospectively as exploratory endpoints in illness trials, and in the end pursuing biomarker qualification or composite scientific endpoints below the FDA Biomarker Qualification Program and FDA-NIH BEST framework. Such an method may floor geroprotective candidates years and even a long time sooner than the standard path of post-approval drug repurposing.
Insilico’s dual-purpose therapeutic technique can also be proving its viability as a sustainable industrial mannequin. Not too long ago, Insilico reported whole income of roughly $106 million within the first half of 2026, a 287% year-over-year improve, and achieved its first worthwhile half-year since itemizing, with an adjusted internet revenue exceeding $51 million. This milestone was pushed by a collection of out-licensing, co-development, and R&D collaborations with international companions, together with Eli Lilly, Servier, Takeda, SK Biopharmaceuticals, Qilu Pharmaceutical, Hygtia Therapeutics, CMS, and Tenacia. As of the most recent practicable date, the overall contract worth of transactions introduced by Insilico in 2026 reached roughly $7.3 billion, pushing the cumulative contract worth of its main collaborations since 2021 roughly $11 billion.
On the AI-driven R&D entrance, Insilico nominated 9 improvement candidates inside 9 months of 2026 as of late August, setting a brand new firm document for annual pipeline productiveness and attaining eight scientific milestones throughout its proprietary and co-developed packages. Main this progress is rentosertib (ISM001-055), the world’s first drug candidate found and developed utilizing generative AI, which has superior to a Part III trial evaluating for idiopathic pulmonary fibrosis (IPF). As well as, Insilico Drugs launched a complete set of benchmarks that permit basis fashions to be evaluated in all duties wanted for drug discovery and launched cutting-edge (SOTA) basis fashions outperforming different fashions and even inside instruments in benchmarks. Utilizing this new functionality Insilico hopes to develop and speed up longevity drug discovery and improvement each by way of scale, therapeutic modalities, and indications.
Trade Commentary and Further Info
“Six proteomic clocks from six impartial teams, utilized to the identical 42 sufferers, all reported a youthful organic age within the handled arms. What convinces me isn’t the dimensions of the impact however the settlement, as a result of these fashions share neither their options nor their coaching knowledge.” stated Michael Levitt, PhD, 2013 Nobel Prize laureate in Chemistry. “This trial can not but separate slower getting older from a handled lung, and the authors say so plainly. The experiment in wholesome volunteers is the one I need to see subsequent.”
“Insilico Drugs was constructed with one goal – to develop a reputable and sustainable enterprise mannequin for the event of frontier deep studying know-how and its utility to sensible getting older analysis and drug discovery with the aim of creating utilizing AI and sensible discovery and improvement of longevity therapeutics. This primary program demonstrates the primary proof of idea for the novel dual-purpose therapeutic concentrating on getting older however proposed towards the age-related illness found in document time making exploratory improvement in a number of indications commercially viable.
At this time, nearly all of Insilico’s 40+ drug packages have twin goal concentrating on getting older and illness in a broad vary of therapeutic areas. By pursuing a reputable biotechnology enterprise mannequin, the corporate reached profitability and established the longevity board, which is uncommon for the publicly-traded frontier biotechnology firm. I’m additionally joyful that the drug carries the title of the true hero of the AI drug discovery revolution, our co-CEO, Dr. Ren.
The social and financial alternative for medicine reversing organic age is huge – trillions of {dollars} and billions of life years. If you happen to add simply 3 additional years to everybody’s lifespan, that interprets into roughly 25 billion life years on the worldwide scale – at present life expectancy, that’s roughly 340 million human lifetimes. Extra lifetimes than humanity misplaced in all of the wars ever fought. If you happen to handle so as to add 3 years to everybody’s life, the drug ought to have the ability to considerably prolong the wholesome portion of life as properly translating into trillions of {dollars} in productiveness and financial savings”, stated Alex Zhavoronkov, PhD, founder and co-CEO of Insilico Drugs.
“On this examine, we evaluated scientific trial knowledge to match the blood proteomic profiles of pulmonary fibrosis sufferers handled with Rentosertib versus placebo”, stated Ludger Goeminne, Analysis Fellow in Drugs at Harvard Medical College, and co-author of the paper. “Utilizing six proteomic getting older clocks together with fashions our crew printed in Cell Metabolism, we noticed vital reductions in predicted organic age throughout a number of organ-specific clocks, and additional pathway evaluation confirmed that Rentosertib’s organic influence extends far past merely lowering fibrosis.”
“Because the developer of PAOPAC (Proteome-Conscious Organ Proxy Ageing Clock), I’m thrilled to see our instrument utilized to the evaluation of the Part IIa scientific trial for rentosertib. Dr. Zhavoronkov and his colleagues are the primary to systematically consider a novel drug candidate utilizing a number of proteomic getting older clocks inside a single scientific trial cohort. The methodologies underlying these clocks vary from conventional machine studying (OrganAge, PAOPAC, PAC) to deep studying (ProtAge, ipfP3GPT), with coaching targets encompassing each chronological age (ProtAge, OrganAgechrono, ipfP3GPT, PAOPAC) and mortality threat (PAC, OrganAgemortality). Throughout the board, these clocks constantly predicted a discount in organic age inside the rentosertib remedy group. This cross-model consistency demonstrates that rentosertib’s impact on aging-related proteomic alerts isn’t a model-specific artifact, however somewhat a extremely strong organic phenomenon.”, stated Professor Jing-Dong Jackie Han, Peking-Tsinghua Heart for Life Sciences, Academy for Superior Interdisciplinary Research, Heart for Quantitative Biology (CQB), China. “Moreover, this examine establishes a comparatively complete workflow for the standardized utility of getting older clocks in scientific trials, masking cohort institution, omics profiling, multi-clock parallel evaluation, end result cross-validation, and mechanistic interpretation. It additionally introduces an modern sensible method to scientific trial design: evaluating getting older biomarkers in parallel throughout trials concentrating on particular indications, significantly age-related ailments. This technique holds nice promise for accelerating the invention and validation of longevity interventions.
Lastly, my congratulations on the breakthrough achieved with rentosertib-an modern drug found in China and clinically evaluated primarily in Chinese language affected person cohorts. As a home Chinese language analysis crew behind the event of getting older clocks, we sit up for witnessing extra industry-academia-research collaborations driving future scientific trials in getting older interventions.”
References
| [1] Zhavoronkov, A., Galkin, F., Chen, S. et al. Integration of proteomic getting older clocks in a section 2a scientific trial helps simultaneous geroprotective evaluation. Nat Biotechnol (2026). https://doi.org/10.1038/s41587-026-03286-y |
| [2] Pun, F. W., Leung, G. H. D., Leung, H. W. et al. Hallmarks of aging-based dual-purpose illness and age-associated targets predicted utilizing PandaOmics AI-powered discovery engine. Ageing (Albany NY) 14, 2475-2506 (2022). https://doi.org/10.18632/aging.203960 |
| [3] Tang, Q., Xiao, D., Veviorskiy, A. et al. AI-Pushed Robotics Laboratory Identifies Pharmacological TNIK Inhibition as a Potent Senomorphic Agent. Ageing Dis 17, 432-451 (2026). https://doi.org/10.14336/AD.2024.1492 |
| [4] Ren, F., Aliper, A., Chen, J. et al. A small-molecule TNIK inhibitor targets fibrosis in preclinical and scientific fashions. Nat Biotechnol 43, 63-75 (2025). https://doi.org/10.1038/s41587-024-02143-0 |
| [5] Xu, Z., Ren, F., Wang, P. et al. A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized section 2a trial. Nat Med 31, 2602-2610 (2025). https://doi.org/10.1038/s41591-025-03743-2 |
About Rentosertib (ISM001-055)
Rentosertib is a probably first-in-class small molecule concentrating on TNIK, developed utilizing Insilico Drugs’s generative AI platform Pharma.AI. TNIK was recognized by way of AI-powered goal discovery as a gene concerned in six hallmarks of getting older, making it a dual-purpose goal for each getting older biology and idiopathic pulmonary fibrosis (IPF). The drug’s discovery, design, preclinical validation, and Part I outcomes have been printed in Nature Biotechnology in March 2024. Part IIa outcomes have been printed in Nature Drugs in June 2025. Rentosertib has entered Part III scientific improvement in China.
About Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis is a persistent, scarring lung illness characterised by progressive and irreversible decline in lung operate. Affecting roughly 5 million individuals worldwide, IPF carries a poor prognosis with a median survival of 3-4 years. Present permitted therapies can gradual illness development however can not cease or reverse it, leaving a major unmet want for disease-modifying therapies.
About Insilico Drugs
Insilico Drugs is a pioneering international biotechnology firm devoted to integrating synthetic intelligence and automation applied sciences to speed up drug discovery, drive innovation within the life sciences, and prolong wholesome longevity to individuals on the planet. The corporate was listed on the Foremost Board of the Hong Kong Inventory Alternate on December 30, 2025, below the inventory code 03696.HK.
By integrating AI and automation applied sciences and deep in-house drug discovery capabilities, Insilico is delivering modern drug options for unmet wants together with fibrosis, oncology, immunology, ache, and weight problems and metabolic issues. Moreover, Insilico extends the attain of Pharma.AI throughout numerous industries, resembling superior supplies, agriculture, dietary merchandise and veterinary drugs.
For extra data, please go to www.insilico.com
